Velan Capital Investment Management LP
ALPHARETTA, GA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$104.6M2026 Q3+ $129.8K options (notional, not included)
Positions43
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.79.8%
What Changed This Quarter?
Top Holdings
PRAX
Praxis Precision Medicines
21.3%
IMMX
Immix Biopharma
10.8%
TARA
Protara Therapeutics
8.3%
STRO
Sutro Biopharma
7.8%
ABVX
Abivax S.A.
6.2%
MPLT
MapLight Therapeutics
6.1%
AVR
Anteris Technologies Global
5.2%
EDSA
Edesa Biotech
5.2%
New / Increased
6 new · 5 increased
EWTXNEW
Edgewise Therapeutics
1.3%
QTTBNEW
Q32 Bio
0.9%
AARDNEW
Aardvark Therapeutics
0.4%
ZLABNEW
Zai Lab
0.2%
ENTANEW
Enanta Pharmaceuticals
0.2%
EDSA
Edesa Biotech
5.2%
+54.9%
MPLT
Maplight Therapeutics
6.1%
+26.7%
Inspiremd
Inspiremd
0.6%
+524.2%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.